Analyze the information and social media posts to determine if the closing price of $bmy will ascend or descend at 2017-03-31. Please respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-03-17,1.7,1.7,-0.3,-1.8,-1.8,1.2,1.5,1.4,0.6,-0.5,-1.9
2017-03-20,-0.1,0.5,-0.3,0.2,0.2,0.8,1.2,1.2,0.6,-0.4,-1.8
2017-03-21,1.4,1.7,-0.6,-1.2,-1.2,1.7,2.4,2.3,1.9,1.1,-0.3
2017-03-22,-1.2,0.1,-2.1,1.2,1.2,0.1,1.1,1.0,0.9,0.1,-1.1
2017-03-23,0.6,1.4,-0.2,-1.0,-1.0,0.6,1.7,2.0,1.9,1.2,0.1
2017-03-24,-0.0,0.6,-0.4,0.2,0.2,0.2,1.1,1.6,1.7,1.1,0.2
2017-03-27,-0.8,0.6,-0.9,0.3,0.3,-0.2,0.7,1.2,1.3,1.0,0.2
2017-03-28,-0.3,0.3,-0.5,0.3,0.3,-0.3,0.3,0.9,1.0,0.8,0.1
2017-03-29,0.4,1.1,-0.0,-0.4,-0.4,0.0,0.4,1.2,1.3,1.3,0.7
2017-03-30,1.1,1.2,-0.2,-1.1,-1.1,1.0,1.2,2.0,2.3,2.3,1.8

2017-03-17: AT_USER you did well with $bmy by buying them when it dropped.|mongo jerry -&gt; "have a drink, have a drive, go out and see what you can find." always gets me in trouble. $lly $bmy  go long baby!!!|b
2017-03-18: bharara was investigating hhs chief tom price - report $amgn $bmy $lly $pfe $aet  via AT_USER|rt AT_USER more AT_USER coverage at #acc17: eliquis smashes xarelto, pradaxa at cutting bleed-related cost
2017-03-19: rt AT_USER $bmy $pfe ¡ªeliquis has become a monster commercial drug based on best-in-class clinical data. some drug mkts work the way¡­|rt AT_USER $bmy $pfe ¡ªeliquis has become a monster commercial d
2017-03-20: rt AT_USER on the fly: top stock stories for monday $dis $sfm $wfm $snap $nktr $ctmx $bmy $arry $sonc |rt AT_USER ctla-4 bound for the clinic, $bmy hands cytomx $200m to kick off an expanded discovery
2017-03-21: insider selling: bristol-myers squibb co $bmy insider sells 5,000 shares of stock  #acn|insider selling: bristol-myers squibb co $bmy insider sells 5,000 shares of stock |insider selling: bristol-myer
2017-03-22: AT_USER what's  all this have to do with $bmy?|the svp &amp; controller of bristol myers (nyse: bmy) is selling shares $bmy |bristol-myers squibb company's svp &amp; controller just disposed of 8,096 
2017-03-23: rt AT_USER bristol failure makes small dent in cxcr4-blocking approach   $bmy|could nektar therapeutics be worth more? AT_USER #stocks $shpg, $bmy, $azn, $nktr, $bayry |bristol failure makes small den
2017-03-24: rt AT_USER $bmy: #opdivo receives positive chmp opinion for squamous head and neck #cancer following platinum-based therapy:|$bmy is in ema33 breakout winning 67.14% in the past. | members have an adv
2017-03-25: $pfe, merck kgaa fourth to market with pd-1/l1 inhibitor  $bmy $rhhby $mrk|$bmy get 14 days #free #premium access on the #1 #stock #app &amp; #trump competition:  #nyctaf #ultra2017|$bmy get 14 days #
2017-03-26: rt AT_USER top 10 overbought names in $spy: $noc $rop $has $amg $aapl $agn $rht $prgo $bmy $ctxs |bristol-myers squibb co $bmy downgraded by vetr inc. to ¡°hold¡± |bristol-myers squibb co $bmy downgra
2017-03-27: $bmy is in three inside up winning 63.64% in the past. |rt AT_USER credit suisse analysis shows value in hypothetical pfizer-bristol merger $pfe $bmy $nvs $gild |rt AT_USER credit suisse analysis show
2017-03-28: rt AT_USER benzinga's option alert recap from march 28  $afsi $alrm $amat $spls $mycc $bmy $kite $casy $res $five|$bmy is in scoop pattern winning 85.71% in the past. |benzinga: benzinga's option aler
2017-03-29: bristol-myers squibb co $bmy director lamberto andreotti sells 34,000 shares |bristol-myers squibb co $bmy director lamberto andreotti sells 34,000 shares |bristol-myers squibb co $bmy director lamber
2017-03-30: #bristolmyerssquibb bristol-myers squibb co director lamberto andreotti sells 34,000 shares. read more:  $bmy|#bristolmyerssquibb bristol-myers squibb co director lamberto andreotti sells 34,000 share
Answer:
Analyze the information and social media posts to determine if the closing price of $bmy will ascend or descend at 2017-03-31. Please respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-03-17,1.7,1.7,-0.3,-1.8,-1.8,1.2,1.5,1.4,0.6,-0.5,-1.9
2017-03-20,-0.1,0.5,-0.3,0.2,0.2,0.8,1.2,1.2,0.6,-0.4,-1.8
2017-03-21,1.4,1.7,-0.6,-1.2,-1.2,1.7,2.4,2.3,1.9,1.1,-0.3
2017-03-22,-1.2,0.1,-2.1,1.2,1.2,0.1,1.1,1.0,0.9,0.1,-1.1
2017-03-23,0.6,1.4,-0.2,-1.0,-1.0,0.6,1.7,2.0,1.9,1.2,0.1
2017-03-24,-0.0,0.6,-0.4,0.2,0.2,0.2,1.1,1.6,1.7,1.1,0.2
2017-03-27,-0.8,0.6,-0.9,0.3,0.3,-0.2,0.7,1.2,1.3,1.0,0.2
2017-03-28,-0.3,0.3,-0.5,0.3,0.3,-0.3,0.3,0.9,1.0,0.8,0.1
2017-03-29,0.4,1.1,-0.0,-0.4,-0.4,0.0,0.4,1.2,1.3,1.3,0.7
2017-03-30,1.1,1.2,-0.2,-1.1,-1.1,1.0,1.2,2.0,2.3,2.3,1.8

2017-03-17: AT_USER you did well with $bmy by buying them when it dropped.|mongo jerry -&gt; "have a drink, have a drive, go out and see what you can find." always gets me in trouble. $lly $bmy  go long baby!!!|b
2017-03-18: bharara was investigating hhs chief tom price - report $amgn $bmy $lly $pfe $aet  via AT_USER|rt AT_USER more AT_USER coverage at #acc17: eliquis smashes xarelto, pradaxa at cutting bleed-related cost
2017-03-19: rt AT_USER $bmy $pfe ¡ªeliquis has become a monster commercial drug based on best-in-class clinical data. some drug mkts work the way¡­|rt AT_USER $bmy $pfe ¡ªeliquis has become a monster commercial d
2017-03-20: rt AT_USER on the fly: top stock stories for monday $dis $sfm $wfm $snap $nktr $ctmx $bmy $arry $sonc |rt AT_USER ctla-4 bound for the clinic, $bmy hands cytomx $200m to kick off an expanded discovery
2017-03-21: insider selling: bristol-myers squibb co $bmy insider sells 5,000 shares of stock  #acn|insider selling: bristol-myers squibb co $bmy insider sells 5,000 shares of stock |insider selling: bristol-myer
2017-03-22: AT_USER what's  all this have to do with $bmy?|the svp &amp; controller of bristol myers (nyse: bmy) is selling shares $bmy |bristol-myers squibb company's svp &amp; controller just disposed of 8,096 
2017-03-23: rt AT_USER bristol failure makes small dent in cxcr4-blocking approach   $bmy|could nektar therapeutics be worth more? AT_USER #stocks $shpg, $bmy, $azn, $nktr, $bayry |bristol failure makes small den
2017-03-24: rt AT_USER $bmy: #opdivo receives positive chmp opinion for squamous head and neck #cancer following platinum-based therapy:|$bmy is in ema33 breakout winning 67.14% in the past. | members have an adv
2017-03-25: $pfe, merck kgaa fourth to market with pd-1/l1 inhibitor  $bmy $rhhby $mrk|$bmy get 14 days #free #premium access on the #1 #stock #app &amp; #trump competition:  #nyctaf #ultra2017|$bmy get 14 days #
2017-03-26: rt AT_USER top 10 overbought names in $spy: $noc $rop $has $amg $aapl $agn $rht $prgo $bmy $ctxs |bristol-myers squibb co $bmy downgraded by vetr inc. to ¡°hold¡± |bristol-myers squibb co $bmy downgra
2017-03-27: $bmy is in three inside up winning 63.64% in the past. |rt AT_USER credit suisse analysis shows value in hypothetical pfizer-bristol merger $pfe $bmy $nvs $gild |rt AT_USER credit suisse analysis show
2017-03-28: rt AT_USER benzinga's option alert recap from march 28  $afsi $alrm $amat $spls $mycc $bmy $kite $casy $res $five|$bmy is in scoop pattern winning 85.71% in the past. |benzinga: benzinga's option aler
2017-03-29: bristol-myers squibb co $bmy director lamberto andreotti sells 34,000 shares |bristol-myers squibb co $bmy director lamberto andreotti sells 34,000 shares |bristol-myers squibb co $bmy director lamber
2017-03-30: #bristolmyerssquibb bristol-myers squibb co director lamberto andreotti sells 34,000 shares. read more:  $bmy|#bristolmyerssquibb bristol-myers squibb co director lamberto andreotti sells 34,000 share
Answer:+Fall